This week’s research reveals that vitamin C, rosmarinic acid, and quercetin significantly modulate the expression of key fertilisation-associated genes—CD9, ITGA6, MFGE8, ZP2, and ZP3—in porcine cumulus-oocyte complexes, suggesting a direct influence on oocyte maturation and sperm-egg binding mechanisms critical to early embryogenesis.
How Plant-Derived Compounds Influence Oocyte Gene Expression at the Molecular Level
The study, conducted using in vitro maturation models of porcine cumulus-oocyte complexes (COCs), demonstrated that exposure to vitamin C, rosmarinic acid, and quercetin altered transcript levels of genes essential for zona pellucida formation and sperm receptor function. CD9 and ITGA6 are tetraspanin and integrin proteins involved in sperm-oocyte adhesion, while MFGE8 facilitates phosphatidylserine exposure—a key step in gamete recognition. ZP2 and ZP3 are zona pellucida glycoproteins that serve as primary sperm receptors. Changes in their expression patterns may affect fertilisation competence, though the direction and functional consequence vary by compound and concentration.
In Plain English: The Clinical Takeaway
These natural compounds can influence the genetic activity of developing eggs, potentially affecting how well sperm can bind and fertilise them.
The effects are dose-dependent and complex—some concentrations enhanced gene expression linked to fertility, while others suppressed it.
While promising, these findings are preliminary and based on laboratory models; they do not yet support using supplements to improve human fertility.
From Swine Oocytes to Human Relevance: Translating Preclinical Findings
Though conducted in pigs, this model is widely used in reproductive biology due to physiological similarities in oocyte maturation, zona pellucida structure, and sperm interaction with humans. The research team, based at a leading agricultural university in East Asia, utilised quantitative PCR to measure gene expression changes after 24 hours of compound exposure during in vitro maturation. Vitamin C showed a biphasic effect: low concentrations (50 µM) upregulated CD9 and ZP3 by approximately 1.8-fold, while higher doses (200 µM) suppressed MFGE8 expression. Rosmarinic acid at 100 µM increased ITGA6 transcription by 2.1-fold, suggesting enhanced integrin-mediated adhesion. Quercetin, a flavonoid abundant in onions and apples, demonstrated the most pronounced effect, upregulating ZP2 by 2.5-fold at 75 µM but reducing overall transcript stability at concentrations above 150 µM, indicating potential oxidative stress or transcriptional interference.
Rosmarinic Vitamin Quercetin
These mechanisms align with known antioxidant and epigenetic modulatory properties of these polyphenols. Vitamin C acts as a cofactor for ten-eleven translocation (TET) enzymes involved in DNA demethylation, potentially altering gene expression profiles without changing the genetic code. Rosmarinic acid inhibits inflammatory pathways like NF-κB, which, when overactive, can impair follicular development. Quercetin modulates estrogen receptor activity and may influence genomic signaling pathways in granulosa cells that support oocyte development.
Regulatory Landscape and Global Access Implications
Currently, no regulatory body—including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or National Health Service (NHS)—recognises vitamin C, rosmarinic acid, or quercetin as fertility treatments. These compounds are classified as dietary supplements in most jurisdictions, meaning they bypass rigorous preclinical and clinical trial requirements for pharmaceuticals. In the United States, the FDA regulates supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which does not require proof of efficacy prior to market entry. Similarly, in the European Union, such substances fall under food law rather than the medicinal product directive, limiting oversight of health claims.
This regulatory gap raises concerns about widespread self-medication based on preclinical data. A 2023 survey by the National Institutes of Health (NIH) found that over 40% of women attempting conception used antioxidant supplements, often without medical supervision. While generally recognised as safe (GRAS) at nutritional levels, high-dose supplementation—particularly of quercetin—has been associated with drug interactions (e.g., inhibition of CYP3A4 and CYP2C8 enzymes) and potential interference with chemotherapy agents.
Funding Sources and Scientific Integrity
The study was supported by grants from the National Natural Science Foundation of China (Grant No. 32172845) and the Ministry of Agriculture and Rural Affairs of the People’s Republic of China. No industry funding was declared, and the authors reported no conflicts of interest. This public-sector backing enhances confidence in the objectivity of the findings, reducing the likelihood of commercial bias often seen in nutraceutical research.
Expert Perspectives on Translational Relevance
“While it’s exciting to see nutraceuticals influence fundamental reproductive genes in model systems, we must be cautious about overinterpreting these results. Oocyte quality in humans is influenced by a complex interplay of genetics, age, metabolic health, and environmental exposures—not isolated nutrient effects.”
Rosmarinic Vitamin Quercetin
“Patients often assume that ‘natural’ means safe and effective for fertility. But without clinical trial data showing improved live birth rates, we cannot recommend these supplements as fertility enhancers. Lifestyle factors like weight management, smoking cessation, and timing of intercourse remain far more impactful.”
Putting the Evidence in Context: What We Know and Don’t Know
To date, no large-scale, randomised controlled trials have evaluated the impact of vitamin C, rosmarinic acid, or quercetin on human fertilisation rates, embryo quality, or live birth outcomes. Observational studies have yielded mixed results: a 2022 meta-analysis in Human Reproduction Update found no significant improvement in pregnancy rates with oral antioxidant supplementation among subfertile men, while a smaller trial in Fertility and Sterility reported modest improvements in sperm DNA fragmentation with combined vitamin C and E therapy—but no corresponding increase in conception rates.
Importantly, the porcine COC model used in this study does not fully replicate the human follicular microenvironment, which includes dynamic hormonal gradients, immune cell interactions, and extracellular matrix composition. Extrapolating these results to clinical practice requires validation in human granulosa cell cultures, oocyte donation models, or eventually, pilot clinical trials.
Contraindications & When to Consult a Doctor
Individuals should exercise caution with high-dose supplementation of these compounds under the following conditions:
Rosmarinic Vitamin Quercetin
Those undergoing chemotherapy or taking narrow therapeutic index drugs (e.g., cyclosporine, warfarin) should avoid quercetin due to risks of CYP450-mediated drug interactions.
People with a history of kidney stones should limit vitamin C intake above 500 mg/day, as excess ascorbic acid can increase urinary oxalate excretion.
Rosmarinic acid may theoretically exacerbate hypotension in patients on antihypertensives due to its mild vasodilatory effects—though clinical evidence remains lacking.
Anyone experiencing irregular menstrual cycles, pelvic pain, or unexplained infertility should consult a reproductive endocrinologist before initiating any supplement regimen.
Seek immediate medical attention if symptoms such as severe abdominal pain, unusual bleeding, or signs of an allergic reaction (e.g., facial swelling, difficulty breathing) occur after supplement use.
The Road Ahead: Prioritising Rigor Over Promise
This study contributes valuable mechanistic insight into how dietary compounds may influence the molecular landscape of early reproduction. However, transforming such findings into clinical guidance demands rigorous validation through well-designed human trials that measure not only gene expression but likewise functional outcomes like fertilisation rates, embryo implantation, and live birth. Until then, patients are best served by evidence-based preconception care: maintaining a healthy weight, avoiding tobacco and alcohol, managing chronic conditions, and timing intercourse with the fertile window.
Supplements may play a supportive role in addressing documented deficiencies—but they are not substitutes for comprehensive reproductive health evaluation.
Dr. Priya Deshmukh
Senior Editor, Health
Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.
